What Eun Dutasteride for AGA Actually Changes in Clinical Practice

At a glance

| Parameter | Detail | |-----------|--------| | N | 917 men (ages 20-50, Hamilton-Norwood IIIv-IV) | | Intervention | Dutasteride 0.5 mg daily | | Comparator | Finasteride 1 mg daily; placebo | | Duration | 24 weeks | | Primary endpoint | Change in target-area hair count (TAHC) vs baseline | | Key result | Dutasteride significantly superior to finasteride on TAHC at week 24 |

Why This Trial Exists

Before 2010, finasteride 1 mg (FDA-approved in 1997) was the only oral 5-alpha reductase inhibitor (5-ARI) with strong phase III data for androgenetic alopecia (AGA). Dutasteride inhibits both type I and type II 5-alpha reductase isoenzymes, whereas finasteride targets only type II. Pharmacologically, that dual inhibition suppresses serum DHT by over 90%, compared with roughly 70% for finasteride (Clark et al., 2004). Clinicians hypothesized this would translate into better hair regrowth, but lacked comparative RCT evidence until Eun et al. published in 2010.

Methodology: What the Abstract Does Not Tell You

The trial enrolled 917 Korean men across multiple dermatology centers. Randomization was 1:1:1 to dutasteride 0.5 mg, finasteride 1 mg, or placebo. Blinding was maintained with matched capsules. The 24-week duration was short relative to the hair cycle (telogen alone spans 2-4 months), and the authors acknowledged this as a limitation in the original publication.

Target-area hair counts used a standardized 1-cm² circular area on the vertex, photographed with a macrophotography system at fixed magnification. Investigators who performed the counts were blinded to group assignment.

Key methodological points often missed:

• Ethnicity homogeneity. All participants were Korean men. Hair diameter, density baselines, and follicular unit groupings differ between East Asian and Caucasian scalps (Lee et al., 2002). Extrapolation to non-Asian populations requires caution.
• Hamilton-Norwood IIIv-IV only. Men with more advanced loss (V-VII) were excluded, so the superiority finding applies to moderate vertex thinning, not broad-pattern baldness.
• No assessment of hair diameter. TAHC measures count, not caliber. A drug that miniaturizes fewer hairs could look equivalent on count alone. The trial did not capture this.

Results: The Numbers Behind the Headline

| Outcome (week 24) | Dutasteride 0.5 mg | Finasteride 1 mg | Placebo | |---|---|---|---| | Mean change in TAHC (hairs/cm²) | +12.2 | +4.7 | -4.6 | | Difference vs finasteride | +7.5 (p < 0.05) |, |, | | Investigator global assessment (improved/greatly improved) | 59.2% | 40.5% | 17.3% | | Adverse event rate (any) | 6.1% | 5.8% | 4.7% |

Dutasteride produced roughly 2.6 times the hair-count increase of finasteride at 24 weeks, a statistically significant and clinically visible difference per the Eun et al. trial data. Investigator-rated improvement was also significantly higher.

Sexual adverse events (decreased libido, erectile dysfunction) occurred at similar low rates across both active arms. No serious adverse events were attributed to either drug. The safety profile at 24 weeks was reassuring, though longer-term data from the dutasteride BPH program showed cumulative sexual AE rates of 6-8% over four years.

What Changed in Guidelines After This Trial

South Korea and Japan

The Japanese Dermatological Association guidelines (2017 update) upgraded dutasteride to a recommendation level A1 for male AGA, citing Eun 2010 as primary evidence. South Korea approved dutasteride 0.5 mg for AGA in 2009, with this trial serving as the key registration dataset. In East Asian practice, dutasteride is now a first-line option equal to finasteride.

United States and Europe

The FDA has not approved dutasteride for AGA. The current Avodart label carries only a BPH indication. The American Academy of Dermatology guidelines (Olsen et al., 2012) mention dutasteride as an option but note the absence of an FDA-approved hair-loss indication. In practice, US dermatologists prescribe dutasteride off-label for finasteride non-responders, citing Eun 2010 as the principal evidence base.

The European Medicines Agency similarly has not extended dutasteride's indication to AGA, though individual countries (notably South Korea and Japan) have done so through national regulatory pathways.

Prescribing Patterns That Actually Shifted

Three concrete prescribing changes trace back to this trial:

1. Second-line escalation became standard. Before Eun 2010, men who failed finasteride had limited oral options. This trial validated a step-up approach: start finasteride, switch to dutasteride if response is insufficient at 12 months. The Shanshanwal et al. 2017 review confirmed this sequential strategy is now common in clinical practice.

2. Dose confidence at 0.5 mg. Earlier dose-finding work (Olsen et al., 2006) tested 0.05-2.5 mg and found 0.5 mg near the top of the dose-response curve. Eun 2010 confirmed that 0.5 mg, the same dose used for BPH, provides meaningful AGA benefit without requiring upward titration.

3. Combination therapy rationale. Clinicians now pair dutasteride with topical minoxidil based on complementary mechanisms. The Eun et al. data established the oral 5-ARI ceiling, prompting combination approaches that add a vasodilator for additive regrowth.

Limitations the Trial Acknowledged

The authors stated several caveats in the original paper:

• 24-week duration. Hair cycling means full drug effect may not manifest until 12-18 months. The superiority margin at 24 weeks could widen or narrow with longer observation.
• Single ethnicity. Generalizability to non-Korean populations remains unproven in a head-to-head format.
• No patient-reported outcomes. The trial used investigator assessments and hair counts, but did not include validated quality-of-life instruments.
• No long-term safety data specific to AGA. The safety profile was extrapolated from the 4-year REDUCE BPH trial, which enrolled older men (50-75 years) rather than the 20-50-year-olds in this study.

What This Means for Patients Who Differ from the Trial Population

Women with AGA: This trial enrolled only men. Dutasteride is category X in pregnancy. For premenopausal women, spironolactone remains the standard oral antiandrogen; dutasteride use in women is limited to postmenopausal cases under specialist supervision (Olsen et al., 2005).

Men over 50: The trial capped enrollment at age 50. Older men may have different follicular senescence patterns. BPH data confirms long-term tolerability in older cohorts, but the hair-count benefit may be attenuated when follicles are fully miniaturized.

Norwood V-VII: Advanced baldness was excluded. Men with extensive vertex and frontal loss should not expect equivalent TAHC gains. Hair transplantation combined with medical therapy is more appropriate at these stages.

Non-Asian populations: A subsequent multinational RCT (Gubelin Harcha et al., 2014) confirmed dutasteride superiority over finasteride in a mixed-ethnicity cohort (N=917 to 6 months), strengthening the generalizability of Eun's findings across racial groups.

The Bottom Line for Practice Today

Eun 2010 did not make dutasteride a universal first-line drug. It made dutasteride a credible, evidence-based escalation for the substantial minority of men who respond inadequately to finasteride. In jurisdictions with regulatory approval (Japan, South Korea), it functions as a co-first-line agent. In the US and EU, it remains the best-studied off-label oral option for AGA, prescribed with informed consent about the off-label status and drawn from the same safety database that supports long-term BPH use.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252-258. PubMed
2. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5-alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023. PubMed
3. Gubelin Harcha W, Barboza Martinez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489-498. PubMed
4. Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005;52(2):301-311. PubMed
5. Japanese Dermatological Association. Guidelines for the management of androgenetic alopecia (2017). J Dermatol. 2018;45(9):1031-1043. PubMed
6. FDA Avodart (dutasteride) prescribing information. AccessData